A Multicentric, Randomized, Phase II Study Evaluating the Combination of METFORMIN With TAXOTERE+ Metformin Placebo Versus TAXOTERE + Metformin for the Treatment of Metastatic Hormone-refractory Prostate Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Docetaxel (Primary) ; Metformin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms TAXOMET
- 07 Jun 2017 Biomarkers information updated
- 25 Jul 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2017.
- 25 Jul 2016 Status changed from recruiting to active, no longer recruiting.